Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naphazoline hydrochloride is a synthetic, direct-acting sympathomimetic amine and imidazole derivative that functions as a potent vasoconstrictor and decongestant. Originally patented in 1934 and introduced into medical use in 1942 by Ciba, the drug acts as an agonist on both alpha-1 and alpha-2 adrenergic receptors. Upon topical administration to the nasal mucosa or conjunctiva, naphazoline stimulates these receptors on vascular smooth muscle, causing rapid constriction of dilated arterioles. This localized vasoconstriction reduces blood flow, edema, and swelling, thereby providing temporary relief from nasal congestion associated with the common cold, sinusitis, and allergic rhinitis, as well as ocular redness and irritation caused by allergic conjunctivitis. It is widely available in over-the-counter (OTC) nasal sprays, nasal drops, and ophthalmic solutions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naphazoline hydrochloride.